NCT05041972
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have HER2+ (HER2 amplified or IHC 3+) breast cancer OR must have a HER2 somatic mutation detected by tests like Guardant360, Foundation One, or others
Exclusions: Patients with unstable brain metastases
https://clinicaltrials.gov/ct2/show/NCT05041972